CDK4 and breast neoplasm: The modest efficacy of anti‐PD‐1 therapy in the presumably “cold” HR+/HER2− breast tumours, the niche of CDK4/6i, provides an opportunity to investigate the immune‐priming effects of cell cycle inhibition as well as the features associated with acquired resistance that could enhance sensitivity to such strategies.